1333242-48-0

Upstream product

• 1333242-46-8 tert-butyl 1-(tosyloxymethyl)-5-nitro-1H-benzo[e]indole-3(2H)-carboxylate 
• 98-59-9 p-toluenesulfonyl chloride 
• 193225-63-7 3-(tert-butoxycarbonyl)-1-(hydroxymethyl)-5-nitro-1,2-dihydro-3H-benzindole 

Downstream Products

• 1333242-25-3 (3-(5-(2-hydroxyethoxy)-1H-indole-2-carbonyl)-5-nitro-2,3-dihydro-1H-benzo[e]indol-1yl)methyl 4-methylbenzenesulfonate 
• 1333242-27-5 (3-(5-methoxy-1H-indole-2-carbonyl)-2,3-dihydro-1H-benzo[e]indol-1-yl)methyl 4-methylbenzenesulfonate 
• 1333242-23-1 (5-nitro-3-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-2,3-dihydro-1H-benzo[e]indol-1-yl)methyl 4-methylbenzenesulfonate 
• 193225-65-9 1-(chloromethyl)-5-nitro-3-<(5,6,7-trimethoxyindol-2-yl)carbonyl>-1,2-dihydro-3H-benzindole 

Relevant academic research and scientific papers

The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycins

A series of 3-substituted (5-nitro-2,3-dihydro-1H-benzo[e]indol-1-yl)methyl sulfonate (nitroCBI) prodrugs containing sulfonate leaving groups undergo hypoxia-selective metabolism to form potent DNA minor groove alkylating agents. They were evaluated (alon